BEAUTY HEALTH COMPANY

The Beauty Health Company Registered A will present results for the quarter ended June 30, 2026, on August 6, 2026. Eight analysts see an average EPS of -0.025 USD per share (prior year: 0.030 USD). Nine analysts expect revenue averaging 74.5 million USD, a decline of 4.78% from 78.2 million USD a year earlier. For the current fiscal year, nine analysts forecast an average loss of -0.157 USD per share and annual revenue of 290.5 million USD (prior year: 300.8 million USD). » More on finanzen.net

Beauty Health Co reported fourth-quarter 2025 revenue of $82.4 million, beating the forecast of $77.73 million, while EPS of -$0.06 missed the expected -$0.05. Adjusted EBITDA rose to $15 million, up 66.7% year over year, driven by a stronger consumables business and disciplined cost management. Management highlights the expansion of the Hydrafacial platform and expects Q2 2026 EPS of $0.01 on revenue of $76.45 million. In after-hours trading the stock jumped 12.89%, with investors reacting positively to the revenue performance and the strategic realignment. » More on de.investing.com

The Beauty Health Company has signed a supplemental agreement to its 7.95% convertible senior notes (maturing 2028) that adds new foreign subsidiaries as first‑priority guarantors and clarifies ambiguities in the original agreement. The guarantees are effectively secured by substantially all assets of the new guarantors, subject to customary exceptions. The company reports strong liquidity and a current ratio of 5.15. Beauty Health also beat expectations in Q2 2025 with EPS of $0.03 and revenue of $78.2 million; Jefferies raised its price target to $2.00 and affirmed its "Hold" rating. » More on de.investing.com